Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 197 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori acquired 197 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of GBX 76 per share, for a total transaction of £149.72.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, November 11th, Ije Nwokori bought 176 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 85 per share, with a total value of £149.60.
• On Wednesday, October 15th, Ije Nwokori sold 298,675 shares of Dr. Martens stock. The stock was sold at an average price of GBX 90, for a total value of £268,807.50.
• On Monday, October 13th, Ije Nwokori purchased 167 shares of Dr. Martens stock. The stock was bought at an average price of GBX 89 per share, for a total transaction of £148.63.
• On Wednesday, October 8th, Ije Nwokori acquired 136 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 90 per share, for a total transaction of £122.40.

Dr. Martens Trading Up 0.6%

LON DOCS traded up GBX 0.50 during trading on Friday, hitting GBX 77.45. The company had a trading volume of 6,999,042 shares, compared to its average volume of 2,302,026. The company’s fifty day moving average is GBX 85.14 and its 200-day moving average is GBX 82.29. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The company has a market cap of £748.44 million, a price-to-earnings ratio of 45.56, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, sell-side analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DOCS has been the topic of a number of research analyst reports. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 27th. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.